FCF Fox Company Finance GmbH is delighted to publish the brand new “FCF Life Sciences Enterprise Capital Monitor – Europe 06/2022”. The Monitor is a month-to-month revealed overview of enterprise...
A latest FCF Life Sciences evaluation confirmed a major decline in funding volumes for European life sciences markets within the first half of 2022 in comparison with 2021. This...
A latest FCF Life Sciences evaluation confirmed a major decline in funding volumes for European life sciences markets within the first half of 2022 in comparison with 2021. This...
Enterprise capital deal volumes within the European life sciences sector reached a record-breaking stage in 2021. Nonetheless, financing volumes decreased considerably by 29% within the first 4 months of...
FCF Fox Company Finance GmbH is delighted to publish the brand new “FCF Life Sciences Enterprise Capital Monitor – Europe 04/2022”. The Monitor is a month-to-month printed overview of enterprise...
Through the first six months of 2022, we discover that the funding for all times sciences markets declined considerably in comparison with 2021. The pattern impacts all related life...
Throughout the first six months of 2022, we discover that the funding for all times sciences markets declined considerably in comparison with 2021. The pattern impacts all related life...
With 44 offers, the company enterprise arm of Boehringer Ingelheim was probably the most lively company investor within the European life science market within the final 5 years. The...
FCF Fox Company Finance GmbH is delighted to publish the brand new “FCF Life Sciences Enterprise Capital Monitor – Europe 05/2022”. The Monitor is a month-to-month printed overview of enterprise...
FCF Fox Company Finance GmbH is delighted to publish the brand new “FCF Life Sciences Enterprise Capital Monitor – Europe 05/2022”. The Monitor is a month-to-month revealed overview of enterprise...